| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Duquesne Family Office · Stanley Druckenmiller | $16.8M | 0.32% | 356.60K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DFTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Sullivan Mark ROfficer | Sale at price 36.57 per share. | 14.1K | $513.85K |
| Sep 24, 2026 | Roberts Brandi LChief Financial Officer | Sale at price 36.57 per share. | 3.4K | $123.50K |
| Sep 24, 2026 | Wiley Matthew TOfficer | Sale at price 36.57 per share. | 3.1K | $113.26K |
| Sep 24, 2026 | Barrow Robert BChief Executive Officer | Sale at price 36.57 per share. | 31.6K | $1.15M |
| Sep 24, 2026 | Karlin Daniel RollingsOfficer and Director | Sale at price 36.57 per share. | 10.9K | $396.89K |
| Sep 13, 2026 | Sullivan Mark ROfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Sep 13, 2026 | Roberts Brandi LChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Sep 13, 2026 | Wiley Matthew TOfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Sep 13, 2026 | Barrow Robert BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 750K | — |
| Sep 13, 2026 | Karlin Daniel RollingsOfficer | Stock Award(Grant) at price 0.00 per share. | 200K | — |
| Sep 2, 2026 | Barrow Robert BChief Executive Officer | Sale at price 37.94 per share. | 19K | $721.73K |
| Sep 1, 2026 | Barrow Robert BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Aug 11, 2026 | Sullivan Mark ROfficer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Aug 11, 2026 | Roberts Brandi LChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Aug 11, 2026 | Wiley Matthew TOfficer | Stock Award(Grant) at price 0.00 per share. | 62.5K | — |
| Aug 11, 2026 | Barrow Robert BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 375K | — |
| Aug 11, 2026 | Karlin Daniel RollingsOfficer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Jun 24, 2026 | Sullivan Mark ROfficer | Sale at price 45.03 per share. | 13K | $585.75K |
| Jun 24, 2026 | Roberts Brandi LChief Financial Officer | Sale at price 45.03 per share. | 3K | $135.68K |
| Jun 24, 2026 | Wiley Matthew TOfficer | Sale at price 45.03 per share. | 2.9K | $129.10K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 26.1 | 3.4 | 8.3 | 15.8 | 10.6 | 94.5 | -7.5 | -8.7 | -4.2 | -8.5 | +160.0% | ||
| 2025 | -2.4 | -1.0 | -12.9 | 9.2 | 13.6 | -10.6 | 40.1 | -2.3 | 32.8 | 20.4 | -10.9 | 5.8 | +92.4% |
| 2024 | 5.5 | 48.1 | 64.5 | 1.3 | -7.6 | -18.1 | 28.4 | -34.6 | -6.1 | 10.7 | 29.7 | -14.8 | +90.2% |
| 2023 | 55.0 | 9.1 | -14.8 | 20.5 | -7.3 | 0.8 | 38.1 | -15.8 | -24.6 | -18.2 | 28.9 | 10.9 | +66.4% |
| 2022 | -18.8 | 8.9 | -9.0 | -27.9 | 13.1 | -29.3 | 8.6 | 12.4 | -70.1 | -16.3 | -13.0 | -13.7 | −89.4% |
| 2021 | -3.3 | 12.5 | -16.0 | 40.1 | -13.0 | 1.5 | -11.3 | -5.6 | -19.4 | 8.2 | -21.4 | -30.3 | −54.8% |
| 2020 | -10.7 | 0.0 | 1020.0 | -19.6 | -11.8 | -6.3 | -14.2 | 14.7 | 63.1 | 29.5 | 114.2 | 84.2 | +5346.4% |
| 2019 | 13.6 | 4.0 | 13.5 | 11.9 | -18.2 | 11.1 | -83.3 | 370.0 | 8.5 | 29.4 | -27.3 | 16.7 | +27.3% |
| 2018 | -22.9 | -37.6 | 7.7 | -2.6 | 0.0 | -40.0 | -21.1 | 40.8 | -16.0 | 2.4 | -37.2 | -18.5 | −85.2% |
| 2017 | 22.0 | 52.2 | -18.0 | -28.6 | -14.6 | 1.0 | -3.3 | -23.9 | -6.3 | -20.8 | -2.1 | 8.0 | −45.9% |
| 2016 | 58.2 | +58.2% |
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Buy / hold / sell counts